Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 4/20 | 0.60 |
| ▸ | GFER | P55789 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 9/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25872106 | 0.89 | KMT2A (0.71) | KAT6AGFERKMT2AMEN1GAA | |
| SCHEMBL25241197 | 0.89 | KMT2A (0.71) | KAT6AGFERKMT2AMEN1GAA | |
| SCHEMBL6396355 | 0.86 | KAT6A (0.78) | KAT6AKMT2AMEN1GAALMNA | |
| SCHEMBL25284025 | 0.84 | KAT6A (0.65) | KAT6AGFERKMT2AMEN1GAA | |
| SCHEMBL5672239 | 0.82 | GFER (0.86) | KAT6AGFERKMT2AGAAL3MBTL1 | |
| SCHEMBL28979677 | 0.82 | GAA (0.76) | KAT6AGFERKMT2AMEN1GAA | |
| SCHEMBL25872095 | 0.77 | KMT2A (0.68) | KAT6AGFERKMT2AMEN1GAA | |
| SCHEMBL4818961 | 0.76 | MEN1 (0.83) | KMT2AMEN1L3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL20567504 | 0.76 | LMNA (0.62) | KAT6AKMT2AMEN1GAAL3MBTL1 | |
| SCHEMBL27581323 | 0.76 | HTR6 (0.67) | KMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4144722-A1 | COMPOUND AS UBR BOX DOMAIN LIGAND | Autotac Inc. (KR) | 2023-03-08 | — | — | EP | claimed |
| CN-115715285-A | Compounds as UBR box domain ligands | 奧土择破利悟 | 2023-02-24 | — | — | CN | claimed |
| US-20230174470-A1 | COMPOUND AS A UBR BOX DOMAIN LIGAND | AUTOTAC INC. (KR) | 2023-06-08 | — | — | US | disclosed |
| EP-4144722-A1 | COMPOUND AS UBR BOX DOMAIN LIGAND | Autotac Inc. (KR) | 2023-03-08 | — | — | EP | disclosed |
| CN-115715285-A | Compounds as UBR box domain ligands | 奧土择破利悟 | 2023-02-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174470-A1 | COMPOUND AS A UBR BOX DOMAIN LIGAND | UBR4, UBQLN2, UBTF | KAT6A 1150/4885GFER 2489/4885KMT2A 1391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.